# A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

> **NCT01626456** · PHASE3 · COMPLETED · sponsor: **Alkermes, Inc.** · enrollment: 478 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** ALKS 9072, Low
- **DRUG:** ALKS 9072, High

## Key facts

- **NCT ID:** NCT01626456
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626456, "A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01626456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*